Navigating Risks in Global Licensing of Chinese Trials

With an uptick in licensing deals and promising data emerging from China-based biopharmas, especially in oncology, it’s clear the country is poised to play a major role in life sciences for the foreseeable future.

In this week’s episode of "The Top Line," we trace China’s ascent in R&D and drug discovery and examine how U.S. and European drugmakers are capitalizing on the momentum through a surge in licensing activity.

Fierce Pharma’s Fraiser Kansteiner sits down with Mark Lansdell, director at Evaluate, to break down the policies fueling China’s growth, how global companies are engaging with Chinese assets and which modalities and indications are commanding the most attention.

To learn more about the topics in this episode: 

• China approves 4 new drugs, including a global first-in-class medicine
• With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs
• China biotechs ‘reshaping’ US biopharma as outlicensing deals rise 11%: Jefferies report
• China proposes shorter clinical trial reviews in efforts to accelerate drug development

See omnystudio.com/listener for privacy information.